Regulus Therapeutics Inc.

NasdaqCM:RGLS Stock Report

Market Cap: US$175.8m

Regulus Therapeutics Past Earnings Performance

Past criteria checks 0/6

Regulus Therapeutics has been growing earnings at an average annual rate of 0.3%, while the Biotechs industry saw earnings growing at 14.5% annually. Revenues have been declining at an average rate of 39.8% per year.

Key information

0.3%

Earnings growth rate

69.0%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-39.8%
Return on equity-141.8%
Net Marginn/a
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Regulus surges 15% after Phase 1 data for kidney disease candidate

Sep 12

Regulus Therapeutics GAAP loss per share narrows

Aug 11

Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

Oct 12
Does Regulus Therapeutics (NASDAQ:RGLS) Have A Healthy Balance Sheet?

The Read On Regulus Therapeutics

Aug 03

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Jun 09
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Regulus Therapeutics Inc.'s (NASDAQ:RGLS) CEO For Now

Regulus reports top-line data from early-stage RGLS4326 trial in polycystic kidney disease

May 03

Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Mar 13
Auditors Are Concerned About Regulus Therapeutics (NASDAQ:RGLS)

Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Mar 10
Introducing Regulus Therapeutics (NASDAQ:RGLS), The Stock That Zoomed 101% In The Last Year

Regulus Therapeutics announces closing of $19.4M private placement

Dec 08

Regulus Therapeutics EPS beats by $0.17, beats on revenue

Nov 05

Revenue & Expenses Breakdown
Beta

How Regulus Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:RGLS Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-30100
30 Sep 230-29100
30 Jun 230-2892
31 Mar 230-2990
31 Dec 220-28100
30 Sep 220-29100
30 Jun 220-30108
31 Mar 220-29100
31 Dec 210-28100
30 Sep 215-22100
30 Jun 2110-1590
31 Mar 2110-1690
31 Dec 2010-1690
30 Sep 205-1990
30 Jun 200-23100
31 Mar 200-21100
31 Dec 197-19110
30 Sep 197-22120
30 Jun 197-27120
31 Mar 197-36130
31 Dec 180-49130
30 Sep 180-55130
30 Jun 180-60130
31 Mar 180-68130
31 Dec 170-72130
30 Sep 170-77150
30 Jun 170-81170
31 Mar 171-81170
31 Dec 161-82180
30 Sep 1612-69190
30 Jun 1614-63220
31 Mar 1617-62210
31 Dec 1521-56190
30 Sep 1514-71170
30 Jun 1513-67120
31 Mar 1510-58120
31 Dec 148-57120
30 Sep 149-36100
30 Jun 1414-2990
31 Mar 1418-2480
31 Dec 1320-1970
30 Sep 1317-2470
30 Jun 1314-2770
31 Mar 1313-2260

Quality Earnings: RGLS is currently unprofitable.

Growing Profit Margin: RGLS is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RGLS is unprofitable, but has reduced losses over the past 5 years at a rate of 0.3% per year.

Accelerating Growth: Unable to compare RGLS's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RGLS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).


Return on Equity

High ROE: RGLS has a negative Return on Equity (-141.77%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.